Michael Kurman
Dialectic Therapeutics · Acepodia Biotech, Inc. · Kyowa Kirin, Inc.
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Michael Kurman as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:49 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT04886622 · A Study of DT2216 in Relapsed/Refractory MalignanciesDialectic Therapeutics, Inc · completed · Solid Tumor, Hematologic Malignancy · study director
- Ph1NCT04319757 · ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid TumorsAcepodia Biotech, Inc. · completed · Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor · study director
- Ph1NCT02358473 · Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung CancerKyowa Kirin, Inc. · completed · Non-Small Cell Lung Cancer · study director
- Ph2NCT01807546 · Oral Rigosertib for Squamous Cell CarcinomaTraws Pharma, Inc. · completed · Head and Neck Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, Lung Squamous Cell Carcinoma · study director
- Ph2NCT01626664 · KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)Kyowa Kirin, Inc. · completed · Adult T-cell Leukemia-Lymphoma · study director
- Ph2NCT01226472 · Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001Kyowa Kirin Co., Ltd. · completed · Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma · study director
- Ph1NCT01199367 · Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast CancerKyowa Kirin Co., Ltd. · terminated · Breast Cancer · study director
- Ph1/Ph2NCT01063907 · A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple MyelomaKyowa Kirin Co., Ltd. · completed · Multiple Myeloma · study director
- Ph1NCT00921336 · Safety Study to Evaluate KW-2450 in Subjects With Advanced Solid TumorKyowa Kirin Co., Ltd. · completed · Solid Tumor · study director
- Ph1/Ph2NCT00888927 · Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell LymphomaKyowa Kirin Co., Ltd. · completed · Peripheral T-Cell Lymphoma · study director
- Ph1/Ph2NCT00838578 · Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal CancerKyowa Kirin Co., Ltd. · terminated · Colorectal Cancer · study director
- Ph1NCT00113724 · Study of TPI 287 in Patients With Advanced MalignanciesCortice Biosciences, Inc. · completed · Neoplasms, Non-Hodgkin Lymphoma, Hodgkin Disease · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:49 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in non-small cell lung cancer.